COVID-19 Continues to Disrupt Patient Care Among Specialty Physicians, Though There Are Early Signs That Recovery is on the Horizon
According to Spherix Global Insights, just one-tenth of specialty physician offices are operating at normal capacity, and doctors report facing multiple challenges with re-opening EXTON, Pa., July 6, 2020 / PRNewswire / – Results from the seventh wave of an ongoing study examining the impact of COVID-19 on specialty physician practices were released last week […]
Nephrologists Are Hesitant to Fully Embrace Janssen’s INVOKANA Despite Being the First and Only SGLT2 Inhibitor with an FDA Indication to Treat Diabetic Kidney Disease
According to Spherix Global Insights’ latest quarterly survey of 101 US nephrologists, despite anticipated increases in use, over one-third of respondents still express some trepidation in prescribing INVOKANA EXTON, Pa., June 18, 2020 / PR Newswire / – Millions of patients across the United States suffer from Type 2 diabetes, and one-quarter or more of […]
Specialty Physicians Report Signs of Rebound from COVID-19, but Are Pessimistic About Reopening Without a Resurgence
According to feedback from the sixth wave of COVID-19 impact tracking, Spherix Global Insights finds that patient volumes remain severely depressed and physicians are worried about patients with non-COVID conditions being able to access care EXTON, Pa., May 27, 2020 / PRNewswire / – Since the end of March, Spherix Global Insights has been tracking […]
Specialty Physicians Predict More Pain Ahead in the Battle Against COVID-19
The impact to practices has been severely disruptive, taking a devastating personal and financial toll on specialty physicians according to the latest update from Spherix Global Insights EXTON, Pa., April 9, 2020 / PRNewswire / – Special Report: Multi-Specialty Impact of COVID-19 is an independent project being run by Spherix to assess the impact of […]
COVID-19 Wreaking Havoc in Specialty Practices and the Vast Majority of Physicians Expect It to Get Worse in the Next Two Weeks, According to a New Report by Spherix Global Insights
Results from a survey of more than 300 dermatologists, gastroenterologists, nephrologists, neurologists, rheumatologists, and primary care physicians indicate a marked decrease in patient visits, growing concern over financial impact to practices, and worry over preparedness for a widespread local outbreak EXTON, Pa., March 24, 2020 / PRNewswire / – Spherix Global Insights is an independent […]
Janssen’s INVOKANA (canagliflozin) Gets Boost Over Competitors with FDA Approval for Diabetic Kidney Disease and a Newly Minted Collaboration with Renal Giant, Vifor Pharma
According to Spherix Global Insights, the approval of INVOKANA was highly anticipated among nephrologists and may present a paradigm shift in the way patients with type 2 diabetes and chronic kidney disease (CKD) are treated in the future EXTON, Pa., November 25, 2019 – It is well-documented that nearly half of patients with type 2 […]
Nephrologists Report Strong Willingness to Prescribe Off-Label Agents for Various Glomerular Diseases, According to Recent Market Intelligence from Spherix Global Insights
Conditions such as diabetic nephropathy, IgA nephropathy, focal segmental glomerulosclerosis (FSGS), and lupus nephritis are associated with high unmet need EXTON, Pa., November 13, 2019/ PRNewswire/ — Throughout 2019, Spherix Global Insights has been collaborating with US nephrologists to identify areas of high unmet need and to detect late-stage clinical candidates with the most promise. […]
US Nephrologists Beginning to Trial AstraZeneca’s LOKELMA (zirconium sodium cyclosilicate) but Unclear on Differentiation from Vifor/Relypsa’s VELTASSA (patiromer FOS)
According to Spherix Global Insights, nephrologists surveyed in August report increased promotion and associated familiarity with Lokelma but express concerns about potential effects of sodium content. EXTON, Pa., / September 17, 2019 / PRNewswire – After two Complete Response Letters resulting in lengthy approval delays, AstraZeneca was finally able to introduce Lokelma, its novel treatment […]
US Nephrologists Are Optimistic About the Potential for Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs) for the Treatment of Renal Anemia
According to Spherix Global Insights, nephrologists have high expectations that this novel class of oral agents may offer a safer way to treat renal anemia compared to erythropoietin stimulating agents (ESAs) such as Amgen’s Epogen and Aranesp EXTON, Pa., August 1, 2019 / PRNewswire/ – In the latest report included in the RealTime Dynamix: Renal […]
US Nephrologists Report Few Gains in the CKD-MBD Market for Akebia’s Auryxia, Amgen’s Parsabiv, and Opko’s Rayaldee Despite Reports That They Would Like to Expand Use of All Three Products
According to the latest quarterly update from Spherix Global Insights, strict protocols at large dialysis organizations (LDOs) are the leading barrier to increased use of Parsabiv while market access pressures remain the primary obstacle for Auryxia and Rayaldee. Download Report Overview JUNE 25, 2019, EXTON, PA – According to a survey of 202 nephrologists in […]
